{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:05:43Z","timestamp":1760169943585},"reference-count":2,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[1999,7,9]],"date-time":"1999-07-09T00:00:00Z","timestamp":931478400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[1999,8]]},"DOI":"10.1038\/sj.bjc.6690595","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:08:00Z","timestamp":1031249280000},"page":"1767-1769","source":"Crossref","is-referenced-by-count":17,"title":["Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice"],"prefix":"10.1038","volume":"80","author":[{"given":"A","family":"Ravaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Bedane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Geoffrois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Lesimple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[1999,7,9]]},"reference":[{"key":"BF6690595_CR1","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1200\/JCO.1996.14.10.2666","volume":"14","author":"BF Cole","year":"1996","unstructured":"Cole, B. F., Gelber, R. D., Kirkwood, J. M., Goldhirsch, A., Barylak, E. & Borden, E. (1996). Quality-of-life adjusted survival analysis of interferon alpha-2b adjuvant treatment of high-risk cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 14: 2666\u20132673.","journal-title":"J Clin Oncol"},{"key":"BF6690595_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","volume":"14","author":"JM Kirkwood","year":"1996","unstructured":"Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C. & Blum, R. H. (1996). Interferon alpha-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14: 7\u201317.","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6690595.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690595","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690595.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:54:46Z","timestamp":1684414486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6690595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,7,9]]},"references-count":2,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["BF6690595"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6690595","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,7,9]]}}}